What ALDA does

ALDA srl is a privately held Italian life science company headquartered at C.E.I.N.G.E. - Advanced Biotechnology in Naples, Italy, that develops and commercializes proprietary reagents and bioassays for advanced fluorescent microscopy and protein-protein interaction (PPI) detection. Its core product is FluoFab, a class of fluorophore-conjugated Fab (antigen-binding fragment) reagents designed for ultra-precision labeling of cellular targets in super-resolution and FRET (Förster Resonance Energy Transfer) microscopy. The company also offers a portfolio of standardized FRET-based bioassays in cell-based, paraffin-embedded tissue (FFPE), and blood formats, with documented expertise in GPCR activation measurement, cytokine receptor activation, and EGFR/ErbB family heterodimerization assays. Underlying capabilities include proprietary fluorophore-Fab conjugation chemistry, in-house analytical protocol design, and access to C.E.I.N.G.E.'s chromatography, mass spectrometry, solid phase, and microfluidic characterization infrastructure.

ALDA serves three primary customer segments: pharmaceutical companies engaged in drug discovery and companion diagnostic development, academic research groups conducting advanced cellular and molecular biology research, and technical/microscopy facilities including EuroBioImaging nodes that provide advanced imaging services. The company is pursuing clinical validation and commercialization of its bioassay technology for diagnostic and prognostic use in oncological and inflammatory pathologies, supported by co-financing under the POR Campania FESR 2014-2020 "Campania Start up 2020" program (CUP B61B19001130007). Revenue is generated through reagent sales, standardized bioassay offerings, and custom assay development services, delivered via a direct, consultative sales motion across a single regional geography (Southern Europe/Italy). The company holds a registered patent on innovative fluorescent probes and methods for protein-protein interaction detection, and has extended its conjugation technology beyond Fab fragments to full-length primary antibodies.

Name

ALDA

Legal name

ALDA srl

Website

https://alda-srl.com

Company type

Private

Operating status

Operating

Short description

ALDA srl is a Naples, Italy-based life science company that develops proprietary FluoFab reagents and FRET-based bioassays for protein-protein interaction detection, serving pharmaceutical companies, academic research groups, and advanced microscopy facilities across Southern Europe.

Ownership category

akta.pro rank

Product category

Life Science Research Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Super-resolution microscopy reagents
• FRET bioassay development
• Protein-protein interaction assays
• Fluorophore-conjugated antibodies
• Companion diagnostic biomarkers

Headquarters

HQ city

Napoli

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. FluoFab Reagents: Sale of FluoFab reagents - fluorophore-conjugated Fab fragments for super-resolution and FRET microscopy applications. Conjugation technology can also be applied to full length primary antibodies.
2. FRET Bioassays: Standardized and customized FRET bioassays for detection of protein-protein interactions including cell-based, FFPE tissue, and blood assays for diagnostic and prognostic purposes.
3. Assay Development Services: Complete assay development service for custom targets and biological matrices, including GPCR activation measurement, cytokine receptor activation, and EGFR family heterodimerization assays.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

ALDA develops and sells FluoFab reagents (fluorophore-conjugated Fab fragments for ultra-precision labeling in super-resolution and FRET microscopy) and FRET bioassays for detecting protein-protein interactions as biomarkers. The company manufactures reagents in-house, characterizes them via chromatography, mass spectrometry, and microfluidic devices, and offers both standardized assays (cell-based, FFPE, blood) and custom assay development services for research, diagnostic, prognostic, and companion diagnostic applications.

Product overview

ALDA offers a dual-product portfolio centered on FluoFab reagents and FRET bioassays. FluoFab is a core reagent product line consisting of fluorophore-conjugated Fab fragments for precision labeling in super-resolution and FRET microscopy. Complementing this, ALDA provides standardized FRET bioassays (cell-based, FFPE, and blood formats) for detecting protein-protein interactions, alongside custom assay development services. The products serve research, diagnostic, prognostic, and companion diagnostic applications.

Differentiator

Problem solved

Functional benefit

Products and services

• FluoFab Reagents A class of reagents comprising fluorophore-conjugated Fab (antigen binding fragments) for ultra-precision labeling of cellular targets, designed for super-resolution and FRET microscopy applications. The conjugation technology can also be applied to full-length primary antibodies. Sold to pharmaceutical companies, academic research groups, and advanced microscopy facilities.
• FRET Bioassays FRET-based bioassays for the detection and quantification of protein-protein interactions as pathological biomarkers, offered in cell-based, FFPE tissue, and blood formats. Used for diagnostic, prognostic, and companion diagnostic applications.
• GPCR Activation Assay FRET assay for measurement of G-protein-coupled receptors activation in human blood cells, specifically related to IL-8 receptor activation or pharmacological inhibition. Used for diagnostic, prognostic, and pharmacological response monitoring.
• Cytokine Receptor Activation Assay FRET assay for measurement of cytokine receptors activation in rheumatoid arthritis patient blood, under development.
• EGFR Family Heterodimerization Assay FRET bioassay for measurement of EGFR/ErbB receptor family heterodimers in paraffin embedded human tissues (FFPE), specifically developed for HER2-HER3 heterodimerization. Used for cancer research including breast cancer.
• Custom FluoFab Design and Production Service Custom design and production of FluoFab according to customer specifications for research lab applications, with conjugation technology that can be applied to full-length primary antibodies.
• Custom Assay Development Service Complete FRET bioassay development service for custom detection and quantification of protein-protein interactions, tailored to specific customer requirements and biological matrices.

Quantifiable outcome

• Detection of protein-protein interactions as biomarkers for oncological and inflammatory pathologies
• +2 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• CEINGE - Advanced BiotechnologiescoreStrategic or Co-development PartnerCEINGE-Advanced Biotechnologies in Naples is a non-profit Consortium operating in molecular biology and advanced biotechnology applied to Human Health. It is an excellence in Italy and abroad for Research and Diagnostics of genetic diseases. ALDA is based at CEINGE facilities and has full access to their infrastructure including mass spectrometry facility.
• EuroBioImaging (EUBI)coreTechnology or IntegrationEuroBioImaging facility in Naples is the Italian Advanced Light Microscopy Node of the European infrastructure 'Euro-BioImaging'. Along with four other imaging facilities in Genoa, Padua, Florence, and Milan, the Node provides access to cutting-edge technologies and complete service packages from sample preparation to image analysis. ALDA works with Eurobioimaging for advanced microscopy services and provides reagents for their imaging experiments.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cell Signaling Technology: Cell Signaling Technology produces high-quality antibodies and reagents for cell signaling research, including validated antibodies for GPCRs, EGFR family members, and PPI studies relevant to ALDA's bioassay targets. It competes in the same research customer segments but offers broader catalog depth rather than niche PPI-focused FRET assays.
• Thermo Fisher Scientific: Thermo Fisher Scientific offers an expansive life sciences tools portfolio spanning antibodies, reagents, custom conjugation services, and assay platforms under brands such as Invitrogen. It competes with ALDA across both FluoFab-style reagents and PPI/bioassay products, though as part of a vastly larger catalog rather than a specialized offering.
• Abcam: Abcam is a broad incumbent in research-grade antibodies and antibody-based reagents, including recombinant antibody fragments and conjugated formats used in super-resolution microscopy. It offers overlapping capabilities to ALDA's FluoFab across a much wider target portfolio and global distribution footprint.
• Eurofins Scientific: Eurofins is a global testing services conglomerate providing bioanalytical, biomarker, and custom assay development services across pharma and diagnostics. It competes with ALDA's assay development service line at much larger scale and geographic reach, though without ALDA's proprietary Fab/FRET reagent specialization.
• Bio-Rad Laboratories: Bio-Rad offers a broad life science research portfolio including antibodies, reagents, bead-based assay systems, and protein interaction analysis tools. Its products overlap with ALDA's research reagent and bioassay offerings but lack the specific Fab-conjugate/FRET specialization that differentiates FluoFab.
• PerkinElmer (Revvity): PerkinElmer, now operating under Revvity, provides life science reagents, assay kits, and detection platforms including AlphaLISA and HTRF alternatives. It overlaps with ALDA in protein-protein interaction detection reagents and custom assay development, but at substantially greater scale and broader application breadth.

Direct peers

• Cisbio (Revvity): Cisbio, now part of Revvity, is the originator of HTRF (Homogeneous Time-Resolved Fluorescence) technology for detecting protein-protein interactions via FRET. It is the closest direct competitor to ALDA's FRET-based bioassay portfolio, serving pharma and academic researchers with standardized PPI detection kits and custom assay development.
• Promega: Promega develops bioluminescent and fluorescence-based assay systems for studying protein-protein interactions, receptor activation, and signaling pathways. Its NanoBRET and custom assay development services are directly comparable to ALDA's FRET bioassay offerings for pharma and academic research customers.
• Jackson ImmunoResearch: Jackson ImmunoResearch specializes in affinity-purified secondary antibodies and antibody fragments (Fab, F(ab')2) conjugated to fluorophores and other labels. It directly competes with ALDA's FluoFab line in offering fluorophore-conjugated Fab fragments for imaging and microscopy applications.
• Rockland Immunochemicals: Rockland Immunochemicals manufactures antibody-based reagents including custom conjugation services and fragment-based products (Fab, F(ab')2) for research and diagnostic applications. It is directly comparable to ALDA's FluoFab offering and custom reagent service model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALDA